secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001193125-25-183719
Event type: litigation
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta sues Pfizer in EU UPC for Paxlovid patent infringement
-------------------------------------------------------------

- Filed suit in Unified Patent Court (action 35071/2025) alleging Pfizer's Paxlovid infringes European Patent EP 4 051 265.
- Action covers 18 EU countries participating in UPC; patent based on July 2020 application for coronavirus protease inhibitors.
- European counterpart of US Patent 11,358,953, which is already subject to ongoing US litigation between Enanta and Pfizer.
- Hearing expected within 12-month UPC target; decision within weeks thereafter, subject to appeal.
- No damages determination yet; if infringement found, separate proceedings would assess damages.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525183719/0001193125-25-183719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312525183719/enta-20250820.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-183719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer